<?xml version='1.0' encoding='utf-8'?>
<document id="28335691"><sentence text="Cases of drug-induced Torsade de Pointes: a review of Belgian cases in the EudraVigilance database." /><sentence text="Post-marketing surveillance is very important, especially for rare adverse drug reactions like QTc-prolongation and Torsade de Pointes (TdP)" /><sentence text=" The objective of this study was to investigate the characteristics of Belgian cases of drug-related TdP reported in the EudraVigilance database" /><sentence text="" /><sentence text="The EudraVigilance database was searched for Belgian post-marketing cases of TdP reported between December 2001-April 2015"><entity charOffset="77-80" id="DDI-PubMed.28335691.s5.e0" text="TdP" /></sentence><sentence text=" These cases were identified with MedDRA preferred terms" /><sentence text=" Duplicate reports were excluded" /><sentence text=" Each included case report was reviewed to collect data about age, gender, seriousness, suspected drug, concomitant drugs, causality, and other known risk factors for QTc-prolongation" /><sentence text="" /><sentence text="Between 2001 and 2015, only 31 cases coded as TdP were identified; 16 cases were also coded as 'prolonged QT' and 2 patients died"><entity charOffset="46-48" id="DDI-PubMed.28335691.s10.e0" text="TdP" /></sentence><sentence text=" In total, 21 suspected drugs were implicated and most of them (N = 11) were part of list 1 of CredibleMeds" /><sentence text=" The most common suspected drugs were citalopram (N = 4) and amiodarone (N = 3)"><entity charOffset="38-48" id="DDI-PubMed.28335691.s12.e0" text="citalopram" /><entity charOffset="61-71" id="DDI-PubMed.28335691.s12.e1" text="amiodarone" /><pair ddi="false" e1="DDI-PubMed.28335691.s12.e0" e2="DDI-PubMed.28335691.s12.e0" /><pair ddi="false" e1="DDI-PubMed.28335691.s12.e0" e2="DDI-PubMed.28335691.s12.e1" /></sentence><sentence text=" In 18 cases, a pharmacodynamic drug-drug interaction with risk of QTc-prolongation was present" /><sentence text=" Most patients (N = 25) had ≥2 other risk factors for QTc-prolongation" /><sentence text="" /><sentence text="Over 15 years, only a low number of Belgian cases of TdP were identified in the EudraVigilance database"><entity charOffset="53-62" id="DDI-PubMed.28335691.s16.e0" text="TdP" /></sentence><sentence text=" In most case reports, multiple risk factors for QTc-prolongation could be detected" /><sentence text=" This illustrates that there is a clear underreporting of QTc-prolongation and TdP in Belgium"><entity charOffset="79-81" id="DDI-PubMed.28335691.s18.e0" text="TdP" /></sentence><sentence text=" Initiatives are needed to improve the awareness and knowledge of health care professionals regarding the risk of QTc-prolongation and TdP, both to prevent cases of TdP and to stimulate the reporting of these cases"><entity charOffset="135-137" id="DDI-PubMed.28335691.s19.e0" text="TdP" /><entity charOffset="165-167" id="DDI-PubMed.28335691.s19.e1" text="TdP" /><pair ddi="false" e1="DDI-PubMed.28335691.s19.e0" e2="DDI-PubMed.28335691.s19.e0" /><pair ddi="false" e1="DDI-PubMed.28335691.s19.e0" e2="DDI-PubMed.28335691.s19.e1" /></sentence><sentence text="" /></document>